세계의 첨단 약물전달 시장 규모 : 제품별, 용도별, 지역별, 범위 및 전망

Advanced Drug Delivery Market Size And Forecast

Advanced Drug Delivery Market size was valued at USD 77.49 Billion in 2024 and is projected to reach USD 303.32 Billion by 2031, growing at a CAGR of 18.60% from 2024 to 2031. Advanced drug delivery regulates the rate at which drugs are released. The type of disease, drug, and preferred outcome all have an impact on the innovation used. An advanced drug delivery system's goal is to deliver a therapeutic amount of medication to a specific site in the body as quickly as possible to achieve and then preserve the target concentration of the drug. The Global Advanced Drug Delivery Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Advanced Drug Delivery Market Definition

Advanced drug delivery systems are optimized methods for delivering the drug molecule to the desired target in a more controlled way. These methods are being developed to enhance the improved therapeutic ratio of existing drugs. The advancement of advanced drug delivery systems is predicated on the delivery of drugs at a predetermined rate, and also slow and targeted delivery for onsite drug release and absorption.

The ability to deliver a drug more selectively to a particular site, easier, more precise, less common dosing, reduced variability in systemic drug levels, absorption that is more constant with the site and mode of action, and reductions in toxic compounds are all major benefits of advanced drug delivery systems over traditional systems.

The Advanced Drug Delivery System is classified as Targeted Drug Delivery, Polymeric Drug Delivery, Sustained Release, Implants & IUDs, and Prodrugs. Targeted drug delivery is a process of providing a drug moiety directly into its intended body area to resolve the specific toxic effect of conventional drug delivery and thus decrease the amount of drug needed for therapeutic efficacy. Prodrugs are molecules with no pharmacological activity that are transformed to the active parent drug in vivo through enzymatic, chemical, or a mixture of the two.

Prodrugs have advanced from being discovered by possibility and used as a salvage effort to just being designed explicitly. The advanced drug delivery system contains oral, parenteral, pulmonary, subcutaneous, transdermal, and carrier-based systems such as nanostructures, Nanospheres, Nanocapsules, nanoparticles, and Nano-sized vesicular carriers including such liposomes, noisome, dendrimers, and synthetic polymer or lipid-based carriers, and other drug delivery systems.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Advanced Drug Delivery Market Overview

One of the major factors driving the growth is the rapid spread of chronic diseases in the overall population. The chronic disease known broadly as a problem that lasts a year or longer and necessarily require ongoing medical care, confine daily activities, or both. Moreover, the substantial increase in global health expenditures has enhanced the Advanced Drug Delivery Market.

The main causes of the increase in medical expenditure are a rise in population, especially geriatrics, an increase in chronic conditions, and enhanced medical service utilization. Growing R&D activities to bring new drug molecules. By developing different advanced drug delivery routes, science and technological advances have been made to develop advanced drug delivery systems to increase the pharmacodynamics, drug toxicity, immunogenicity, biocompatibility, pharmacokinetic properties, and efficacy of drug compounds.

Furthermore, increased government funding and financing, new products, and collaborative partnerships for the development of advanced drug delivery systems are projected to boost market growth over the forecast period. The substantial rise in the number of drugs recalls and drug failures are expected to restrict the growth of the Advanced Drug Delivery Market. Certain technical difficulties in method development, stricter regulations, high pricing for advanced products, and non-availability in low-income countries are among the factors that limit Global Advanced Drug Delivery Market growth.

The increase in healthcare costs has been attributed to the increased consumer awareness of health, enhanced government and corporate initiatives, and government investment by public-private sector companies to fulfill consumer demands in underdeveloped and developing countries. As an outcome, all of these factors provide opportunities for investments in the Research and innovation process and the development of advanced drug delivery solutions for improved drug efficacy and secure therapy for existing drugs as well as upcoming novel molecular entities, which accelerates the market growth.

Global Advanced Drug Delivery Market Segmentation Analysis

The Global Advanced Drug Delivery Market is segmented on the basis of Product, Application, And Geography.

Advanced Drug Delivery Market, By Product

• Polymeric Drug Delivery
• Implants & IUD's
• Sustained Release
• Targeted Drug Delivery
• Prodrugs

Based on Product, The market is segmented into Polymeric Drug Delivery, Implants & IUD's, Sustained Release, Targeted Drug Delivery, and Prodrugs. Targeted Drug Delivery has the highest growing segment of the Global Drug Delivery System Market because of increased drug accessibility, reduced toxicity, effective targeted therapy, and lowered active drug degradation over the forecasted period.

Advanced Drug Delivery Market, By Application

• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers/Clinics
• Home Care Settings
• Others

Based on the Application, The market is segmented into Hospitals, Diagnostic Centers, Ambulatory Surgical Centers/Clinics, Home Care Settings, and Others. Hospitals have the fastest-growing segment of the Global Drug Delivery System Market. because of a rise in the number of in-patients and out-patient visits, However, this leading to an increase in chronic illnesses including such neurology, cardiology, and orthopedics, as well as a growth of the market for drug delivery treatment, the highly specialized clinics segment accounting for almost half of the global Advanced Drug Delivery Market.

Advanced Drug Delivery Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world
• On the basis of Geography, The Global Advanced Drug Delivery Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America is projected to be the largest growing market throughout the forecasted period. This is attributed to the increase in the integration of advanced as a result of improved drug delivery solutions, and increasing healthcare expenses in the region over the projected period.

Key Players

• The "Global Advanced Drug Delivery Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• GlaxoSmithKline, Merck & Co, Antares Pharma, Allergan, F. Hoffmann-La Roche, Novartis, Sanofi, 3M, Johnson & Johnson, Pfizer, Abbott Laboratories, Bayer.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In February 2019, Sandoz, a Novartis division and world leader in biosimilars, received European Commission authorization in Spain for its adalimumab biosimilar, HYRIMOZ, for subcutaneous injection in a syringe or a prefilled pen.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ADVANCED DRUG DELIVERY MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL ADVANCED DRUG DELIVERY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Implants & IUD's
• 5.3 Sustained Release
• 5.4 Targeted Drug Delivery
• 5.5 Prodrugs
• 5.6 Polymeric Drug Delivery

6 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Diagnostic Centres
• 6.3 Ambulatory Surgical Centers/Clinics
• 6.4 Home Care Settings
• 6.5 Hospitals
• 6.6 Others

7 GLOBAL ADVANCED DRUG DELIVERY MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.3 Canada
  • 7.2.4 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL ADVANCED DRUG DELIVERY MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 GlaxoSmithKline
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 Merck & Co
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Antares Pharma
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Allergan
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 F. Hoffmann-La Roche
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Novartis
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Sanofi
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 3M
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 Johnson & Johnson
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments
• 9.10 Pfizer
  • 9.10.1 Overview
  • 9.10.2 Financial Performance
  • 9.10.3 Product Outlook
  • 9.10.4 Key Developments

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research